Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05812326Phase 1Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Role: collaborator

NCT03706326Phase 1Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Role: collaborator

NCT03525652Phase 1Unknown

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Role: collaborator

NCT03525782Phase 1Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Role: collaborator

All 4 trials loaded